Trump announces 100% chip tariff as Apple ups U.S. investment
Investing.com - Standard Biotools reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Standard Biotools announced earnings per share of $-0.370 on revenue of $25.65M. Analysts polled by Investing.com EPS of $-0.130 on revenue of $30.95M.
Standard Biotools 's are down 16% and is trading at $0.980 , still down 80.75% from its 52 week high of $5.09 set on Friday, November 12, 2021.
Standard Biotools follows other major Healthcare sector earnings this month
Standard Biotools's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar